Pain Part 2 Flashcards
Strong agonists
Fentanyl
Hydromorphone
Methadone
Morphine
Tramadol
Mild-to-moderate agonists
Codeine
Hydrocodone
Oxycodone
Propoxyphene
Mixed Agonist-Antagonists
Buprenorphine
Butorphanol
Nalbuphine
Pentazocine
Buprenorphine duration of action
SL: 6-12 hours
IM: 6 hr
Antagonists
Naloxone (Narcan)
Naltrexone
Naloxone duration of action
IV: 30-120 min
Multimodal Pain Management
Utilize various mechanisms of action to target pain at different receptors
Goal: smallest possible doses = less adverse effects
Goal: reduce opioid requirement
Central effects of opioids
Drowsiness
Mental slowing
Euphoria
Respiratory depression
Orthostatic hypotension
peripheral effects of opioids
Constipation
Nausea/vomiting
Urinary retention
Bronchospasm
Opioid-Induced Hyperalgesia
Compensatory increase in glutamate pathways, which promotes pain responses by stimulating NMDA receptors
Patients simply may not respond to opioids even before tolerance develops
PCA loading dose
Establish analgesia
PCA demand dose
Self-administered dose
Can track “successful” vs total demands to determine if parameters areappropriate for patient
Successful = self-administered outside of lockout interval
Unsuccessful = dose attempted during lockout interval
PCA lockout interval
Required interval between doses
PCA interval limits
limits usually set for max amount of drug in a 1 or 4 hr period- is a safety feature but if not calculated correctly can lead to the patient being undertreated for a period of time
total dose per limit
PCA background infusion
Small, continuous dose maintains background analgesia
Useful when the patient is asleep or unable to activate the pump
May lead to over sedation and increased side effects